WO2022189459A3 - Nouvel inhibiteur de galectines à base de galactoside - Google Patents
Nouvel inhibiteur de galectines à base de galactoside Download PDFInfo
- Publication number
- WO2022189459A3 WO2022189459A3 PCT/EP2022/055945 EP2022055945W WO2022189459A3 WO 2022189459 A3 WO2022189459 A3 WO 2022189459A3 EP 2022055945 W EP2022055945 W EP 2022055945W WO 2022189459 A3 WO2022189459 A3 WO 2022189459A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- fibrosis
- cirrhosis
- liver
- diseases
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical class OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 title 1
- 102000007563 Galectins Human genes 0.000 title 1
- 108010046569 Galectins Proteins 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 7
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 5
- 230000004761 fibrosis Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000007882 cirrhosis Effects 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 2
- 230000001476 alcoholic effect Effects 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 abstract 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010055665 Corneal neovascularisation Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 abstract 1
- 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026350 Inborn Genetic disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010072877 Intestinal fibrosis Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010027406 Mesothelioma Diseases 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 abstract 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 208000038012 SSc-Interstitial Lung disease Diseases 0.000 abstract 1
- 206010039491 Sarcoma Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000031737 Tissue Adhesions Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010002906 aortic stenosis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- -1 beta D-galactopyranose compound Chemical class 0.000 abstract 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 abstract 1
- 201000009036 biliary tract cancer Diseases 0.000 abstract 1
- 208000020790 biliary tract neoplasm Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000000159 corneal neovascularization Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000003205 diastolic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000016361 genetic disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000011379 keloid formation Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 206010033103 otosclerosis Diseases 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003214 pyranose derivatives Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000036573 scar formation Effects 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 208000010157 sclerosing cholangitis Diseases 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un composé bêta D-galactopyranose de formule (I). Le cycle pyranose est le β-D-galactopyranose, et ces composés sont des inhibiteurs de galectine-3 à haute affinité destinés à être utilisés dans le traitement d'une inflammation ; d'une fibrose, telle qu'une fibrose pulmonaire, une fibrose hépatique, une fibrose rénale, une fibrose ophtalmologique et une fibrose de la peau et du cœur ; de la cicatrisation ; de la formation de chéloïde ; de la formation de cicatrices aberrantes ; d'adhésions chirurgicales ; de la sclérodermie ; de la sclérose systémique ; d'un choc septique ; d'un cancer tels que les carcinomes, les sarcomes, les leucémies et les lymphomes, tels que les lymphomes à lymphocytes T ; de la formation de métastases de cancers ; de maladies auto-immunes telles que le psoriasis, la polyarthrite rhumatoïde, la maladie de Crohn, la colite ulcéreuse, la fibrose intestinale, la spondylarthrite ankylosante, le lupus érythémateux disséminé ; de troubles métaboliques ; d'une cardiopathie ; d'une insuffisance cardiaque ; d'une sténose aortique ; d'une athérosclérose, d'une angiogenèse pathologique, telle que l'angiogenèse oculaire ou une maladie ou un état associé à l'angiogenèse oculaire, par exemple une néovascularisation associée à un cancer ; et de maladies oculaires, telles que la dégénérescence maculaire liée à l'âge et la néovascularisation cornéenne ; d'une athérosclérose ; de maladies métaboliques telles que le diabète ; le diabète de type 2 ; la résistance à l'insuline ; l'obésité ; l'insuffisance cardiaque diastolique ; l'asthme et d'autres maladies pulmonaires interstitielles, y compris le syndrome de Hermansky-Pudlak, l'hypertension artérielle pulmonaire, la RA-ILD, la SSc-ILD, d'une maladie pulmonaire à fibrose telle que la BPCO et l'asthme. Ces composés peuvent en outre être utilisés dans le traitement d'une otosclérose, d'un mésothéliome ; de troubles hépatiques, tels que la stéatohépatite non alcoolique ou la stéatose hépatique non alcoolique, la cirrhose du foie de diverses origines, telles que la cirrhose auto-immune alcoolique ou non alcoolique comme la cirrhose biliaire primitive et la cholangite sclérosante, une cirrhose induite par un virus, une cirrhose induite par une maladie génétique. Ces composés peuvent par ailleurs être utilisés dans le traitement d'un cancer du foie, d'un cholangiocarcinome, d'un cancer des voies biliaires ; de troubles neurodégénératifs tels que la maladie de Parkinson, la maladie d'Alzheimer, d'une déficience cognitive, de maladies cérébrovasculaires telles qu'un accident vasculaire cérébral, un traumatisme crânien, la maladie de Huntington, la sclérose latérale amyotrophique, la sclérose en plaques, la néphropathie périphérique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21161714.7 | 2021-03-10 | ||
| EP21161714 | 2021-03-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2022189459A2 WO2022189459A2 (fr) | 2022-09-15 |
| WO2022189459A3 true WO2022189459A3 (fr) | 2022-11-10 |
Family
ID=74870683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2022/055945 WO2022189459A2 (fr) | 2021-03-10 | 2022-03-08 | Nouvel inhibiteur de galectines à base de galactoside |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022189459A2 (fr) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020104335A1 (fr) * | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Inhibiteurs alpha-d-galactoside de galectines |
| WO2021001538A1 (fr) * | 2019-07-03 | 2021-01-07 | Galecto Biotech Ab | Nouvel inhibiteur de galectines du type galactoside |
| WO2021028570A1 (fr) * | 2019-08-15 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
| WO2021028323A1 (fr) * | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | Dérivés de (2-acétamidyle)thio-bêta-d-galactopyranoside |
| WO2021028336A1 (fr) * | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | Dérivés (hétéro)aryl-méthyl-thio-bêta-d-galactopyranoside |
-
2022
- 2022-03-08 WO PCT/EP2022/055945 patent/WO2022189459A2/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020104335A1 (fr) * | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Inhibiteurs alpha-d-galactoside de galectines |
| WO2021001538A1 (fr) * | 2019-07-03 | 2021-01-07 | Galecto Biotech Ab | Nouvel inhibiteur de galectines du type galactoside |
| WO2021028323A1 (fr) * | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | Dérivés de (2-acétamidyle)thio-bêta-d-galactopyranoside |
| WO2021028336A1 (fr) * | 2019-08-09 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | Dérivés (hétéro)aryl-méthyl-thio-bêta-d-galactopyranoside |
| WO2021028570A1 (fr) * | 2019-08-15 | 2021-02-18 | Idorsia Pharmaceuticals Ltd | Dérivés de 2-hydroxycycloalcane-1-carbamoyle |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022189459A2 (fr) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101541629B1 (ko) | 2-(5-브로모-4-(4-사이클로프로필나프탈렌-1-일)-4ｈ-1,2,4-트리아졸-3-일티오)아세트산의 다형 및 이의 용도 | |
| JP5701308B2 (ja) | 新規血管漏出遮断剤 | |
| JP2008200039A5 (fr) | ||
| JP2012515724A5 (fr) | ||
| JP2015504909A5 (fr) | ||
| JPH09511753A (ja) | コレステロール吸収阻害薬とコレステロール合成阻害薬の併用 | |
| US11945826B2 (en) | Hydroxypyridoxazepines as NRF2 activators | |
| CN109153672B (zh) | Trpv4拮抗剂 | |
| JP2018505199A (ja) | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 | |
| WO2022189459A3 (fr) | Nouvel inhibiteur de galectines à base de galactoside | |
| NZ594244A (en) | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof | |
| WO2005121135A1 (fr) | Inhibiteur de vla-4 | |
| JP2009520006A (ja) | コレスト−４−エン−３−オンオキシムの新規誘導体、それを含む医薬組成物及び製造方法 | |
| TW200823206A (en) | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine | |
| WO2009005838A3 (fr) | Procédé de préparation d'une solution basique non corrosive et ses procédés d'utilisation | |
| US20230063538A1 (en) | Large scale process | |
| RU2021130616A (ru) | Производные рапамицина, содержащие изотиазолидин-1,1-диоксид и 1,4-бутансультон, и пути их применения | |
| JPWO2020194209A5 (fr) | ||
| RU2021120838A (ru) | Производные рапамицина | |
| JP2020508341A5 (fr) | ||
| JPWO2020128861A5 (fr) | ||
| EP3209661B1 (fr) | Procédé de préparation d'un polymorphe de rivaroxaban | |
| US20240059728A1 (en) | Novel galactoside inhibitor of galectins | |
| JPS61267539A (ja) | 安息香酸誘導体およびその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22712357 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22712357 Country of ref document: EP Kind code of ref document: A2 |